Walter Ageno – Splanchnic Veins
The management of patients with splanchnic vein thrombosis is challenging because of the potential severity of the clinical presentation and because of the substantial risk of short and long-term complications, including recurrences and bleeding.
Evidence to drive clinical decisions is limited because no randomized controlled trials have been carried out in this setting and because of the heterogeneity of the patient population.
Aim of this webinar is to review available evidence in this setting and to discuss possible strategies for the management of patients with splanchnic vein thrombosis and the use of anticoagulant drugs in this setting.
Jonathan Coutinho – Cerbral Sinus
In this presentation Dr. Coutinho will cover the epidemiology, diagnosis and treatment of cerebral venous thrombosis.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
More information and online registration: http://academy.isth.org/
This meeting is being supported by Instrumentation Laboratory
Internists, haematologists, vascular phyisicians
At the end of this Webinar, the participants will be able to:
- To review main risk factors, acute phase and long-term management strategies of splanchnic vein thrombosis, with particular focus on the use of anticoagulant therapies.
- Knowledge on the risk factors for CVT and how these differ from VTE
- Be familiar with the range of clinical manifestations that can observed in patients with CVT
- Recognize the different brain parenchymal lesions that can occur in patients with CVT
- Have an understanding on the different treatment modalities for CVT and know which therapy should be reserved for which patient
Faculty & credentials:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
|Geoffrey Barnes, MD||Portola||Consulting|
|Blue Cross Blue Shield of Michigan||Research|
|Chris Ward, PhD||Bayer||Speaker|
|Boehringer-Ingelheim||Speaker, Advisory Board|
|BMS/Pfizer||Speaker, Advisory Board|
|Yukio Ozaki||The Sysmex Corporation||Advisory Board|
|Jonathan Coutinho||Boehringer Ingelheim||Committee member|
|Walter Ageno||Bayer, Boehringer Ingelheim||Principal Investigator, Advisory Board|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
Lacey Schmeidler, MA
+1 (919) 929-3807
09/21/2016 - 9:00am to 10:00am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.